Related references
Note: Only part of the references are listed.Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases
Kai Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Direct Comparison of Xpert MTB/RIF Assay with Liquid and Solid Mycobacterial Culture for Quantification of Early Bactericidal Activity
Xavier A. Kayigire et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis
Kapil Tahlan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Evaluation of a Mouse Model of Necrotic Granuloma Formation Using C3HeB/FeJ Mice for Testing of Drugs against Mycobacterium tuberculosis
Emily R. Driver et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action
Katherine A. Sacksteder et al.
FUTURE MICROBIOLOGY (2012)
SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro
Venkata M. Reddy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
Andreas H. Diacon et al.
LANCET (2012)
Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide
Robert S. Wallis et al.
PLOS ONE (2012)
Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients
A. H. Diacon et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2011)
Location of Intra- and Extracellular M. tuberculosis Populations in Lungs of Mice and Guinea Pigs during Disease Progression and after Drug Treatment
Donald R. Hoff et al.
PLOS ONE (2011)
Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients
Andreas H. Diacon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In Vitro Interactions between New Antitubercular Drug Candidates SQ109 and TMC207
Venkata M. Reddy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacogenetics of Phase I and Phase II Drug Metabolism
Severine Crettol et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis
R. Rustomjee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β-Hydroxycholesterol
K. P. Kanebratt et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients
Rovina Ruslami et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Drug therapy of experimental tuberculosis (TB): Improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs
Boris V. Nikonenko et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro
Ping Chen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Interspecies pharmacokinetics and in vitro metabolism of SQ109
L Jia et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug
J Jia et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines
M Protopopova et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Pharmacokinetic interactions with rifampicin - Clinical relevance
M Niemi et al.
CLINICAL PHARMACOKINETICS (2003)
Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19
KS Yu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis
I Kramnik et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity
BA Hamelin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
